01071nas a2200181   4500000000100000008004100001260000800042653001600050653002200066653002100088653002800109100001700137700001400154245019200168856004300360490000600403520048000409       2019                            d  bBMJ10aElimination10aSleeping sickness10aFinancial burden10aAfrican trypanosomiasis1 aSutherland S1 aTediosi F00aIs the elimination of ‘sleeping sickness’ affordable? Who will pay the price? Assessing the financial burden for the elimination of human African trypanosomiasis in sub-Saharan Africa  uhttps://gh.bmj.com/content/4/2/e0011730 v43 a<p>Programme to eliminate neglected tropical diseases (NTDs) have gained global recognition, and may allow for improvements to universal health coverage and poverty alleviation. It is hoped that elimination of human African trypanosomiasis (HAT) Trypanosoma brucei gambiense (Tbg) would assist in this goal, but the financial costs are still unknown. The objective of this analysis was to forecast the financial burden of direct costs of HAT Tbg to funders and society.</p>